Business and Finance
Source: (remove) : Dealbreaker
RSS • JSON • XML • CSV
Business and Finance
Source: (remove) : Dealbreaker
RSS • JSON • XML • CSV

Pharma Firms Mallinckrodt and Endo Agree to Merge in $6.7B Cash and Stock Deal


Published on 2025-03-14 17:00:53 - Dealbreaker
  Print publication without navigation

  • When the deal closes, Endo will become a wholly owned subsidiary of Mallinckrodt. The combined company will take on a yet-to-be-determined name and is expected to trade on the New

Mallinckrodt and Endo International have agreed to merge in a deal valued at $6.7 billion, combining their operations in a strategic move to enhance their market position in the pharmaceutical industry. The merger, which includes both cash and stock, aims to create a more robust entity capable of tackling the challenges of the pharmaceutical market, including regulatory pressures and competition. This consolidation is expected to streamline operations, reduce costs, and potentially accelerate the development and distribution of new treatments. The agreement comes at a time when both companies are facing various legal and financial issues, including Mallinckrodt's ongoing bankruptcy proceedings and Endo's efforts to manage its debt. The merger is subject to approval by shareholders and regulatory bodies.

Read the Full Dealbreaker Article at:
[ https://www.msn.com/en-us/money/companies/pharma-firms-mallinckrodt-and-endo-agree-to-merge-in-6-7b-cash-and-stock-deal/ar-AA1AWwnt ]